HUP0302302A2 - Morfolin-acetamid-származékok gyulladásos betegségek kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents
Morfolin-acetamid-származékok gyulladásos betegségek kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0302302A2 HUP0302302A2 HU0302302A HUP0302302A HUP0302302A2 HU P0302302 A2 HUP0302302 A2 HU P0302302A2 HU 0302302 A HU0302302 A HU 0302302A HU P0302302 A HUP0302302 A HU P0302302A HU P0302302 A2 HUP0302302 A2 HU P0302302A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- heteroaryl
- aryl
- alkyl
- atom
- Prior art date
Links
- BWRNWWSQZROEOA-UHFFFAOYSA-N 2-morpholin-4-ylacetamide Chemical class NC(=O)CN1CCOCC1 BWRNWWSQZROEOA-UHFFFAOYSA-N 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 101100244083 Arabidopsis thaliana PKL gene Proteins 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000002950 monocyclic group Chemical group 0.000 abstract 3
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 3
- 125000004434 sulfur atom Chemical group 0.000 abstract 3
- 101001043818 Mus musculus Interleukin-31 receptor subunit alpha Proteins 0.000 abstract 2
- 101150020251 NR13 gene Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
Abstract
A találmány szerinti vegyületek (I) általános képletében R1 jelentésealkilcsoport, alkenilcsoport, alkinilcsoport, alkinil-Y1-, aril-Y1-,heteroaril-Y1-, aril-(O)t-aril-Y1-, aril-(O)t-heteroaril-Y1-,heteroaril-(O)t-aril-Y1-, heteroaril-(O)t-heteroaril-Y1-, alkenil-Y1-,aril-O-Y1-, heteroaril-O-Y1-, alkil-SO2-Y1-, MY1-, J2-Y1- képletűcsoport, cianocsoport vagy cikloalkil-Y1- vagy cikloalkenil-Y1 képletűcsoport, ahol a cikloalkilcsoport és cikloalkenilcsoport adott esetbenegy vagy több hidroxilcsoporttal vagy alkilcsoporttal szubsztituálvalehet, R2 jelentése hidrogénatom vagy alkilcsoport, X jelentéseetiléncsoport vagy CReRf képletű csoport, ahol Re és Rf jelentéseegymástól függetlenül hidrogénatom vagy alkilcsoport, vagy Re és Rfjelentése a kapcsolódó szénatommal együtt cikloalkilcsoport, R3 és R4jelentése egymástól függetlenül hidrogénatom vagy alkilcsoport, Zjelentése közvetlen kötés, CO, CHR6(CH2)n, CHR6(CH2)nO vagyCHR6(CH2)nCO képletű csoport, R5 jelentése fenilcsoport, amely adottesetben szubsztituálva lehet vagy tiofenilcsoport, amely adott esetbenszubsztituálva lehet, R6 jelentése hidrogénatom, alkilcsoport, CONR7R8vagy COO-alkil képletű csoport, a és b értéke 1, n értéke 0-4, J2jelentése (K) általános képletű csoport, ahol X1 jelentése oxigénatom,NR13 vagy kénatom, X2 jelentése CH2, oxigénatom, NR10 vagy kénatom, m1 értéke 1-3, m2 értéke 1-3, azzal a megszorítással, hogy m1+m2értéke 3-5, azzal a további megszorítással, hogy ha X1 és X2 jelentéseegyidejűleg oxigénatom, NR13, NR10 vagy kénatom, akkor m1 és m2 értékelegalább 2, ahol a (K) csoport adott esetben egy vagy több csoporttalszubsztituálva lehet és adott esetben monociklusos arilcsoporttal vagyheteroarilcsoporttal fúzionálva lehet, R7, R8, R9, R10, R13, R14 ésR15 jelentése egymástól függetlenül hidrogénatom vagy alkilcsoport,R11 és R12 jelentése egymástól függetlenül hidrogénatom vagyalkilcsoport, vagy R11 és R12 jelentése a kapcsolódó nitrogénatommalegyütt morfolinilcsoport, piperidinilcsoport vagy pirrolidinilcsoport,M jelentése cikloalkilcsoport vagy cikloalkenilcsoport, amely egymonociklusos arilcsoporttal vagy monociklusos heteroarilcsoporttalfuzionálva van, t értéke 0 vagy 1, Y1 jelentése metiléncsoport,etiléncsoport vagy ciklopropilcsoport. A találmány kiterjed a fentivegyületek előállítására és ezeket tartalmazó gyógyszerkészítményekre. Ó
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0023902A GB0023902D0 (en) | 2000-09-29 | 2000-09-29 | Therapeutically useful compounds |
GB0107644A GB0107644D0 (en) | 2001-03-27 | 2001-03-27 | Therapeutically useful compounds |
PCT/GB2001/004345 WO2002026722A1 (en) | 2000-09-29 | 2001-09-28 | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0302302A2 true HUP0302302A2 (hu) | 2003-12-29 |
Family
ID=26245078
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0302302A HUP0302302A2 (hu) | 2000-09-29 | 2001-09-28 | Morfolin-acetamid-származékok gyulladásos betegségek kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
Country Status (18)
Country | Link |
---|---|
US (4) | US7101882B2 (hu) |
EP (1) | EP1324990B1 (hu) |
JP (1) | JP5089846B2 (hu) |
KR (1) | KR20030031198A (hu) |
CN (1) | CN1678594A (hu) |
AR (1) | AR035205A1 (hu) |
AU (1) | AU2001290143A1 (hu) |
BR (1) | BR0114323A (hu) |
CA (1) | CA2423251A1 (hu) |
CZ (1) | CZ20031195A3 (hu) |
ES (1) | ES2527688T3 (hu) |
HU (1) | HUP0302302A2 (hu) |
IL (1) | IL155093A0 (hu) |
MX (1) | MXPA03002814A (hu) |
NO (1) | NO20031442L (hu) |
NZ (1) | NZ525056A (hu) |
PL (1) | PL362711A1 (hu) |
WO (1) | WO2002026722A1 (hu) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030031198A (ko) * | 2000-09-29 | 2003-04-18 | 글락소 그룹 리미티드 | 염증 질환 치료용 모르폴린-아세트아미드 유도체 |
AU2002224885A1 (en) * | 2000-11-28 | 2002-06-11 | Smithkline Beecham Plc | Morpholine derivatives as antagonists of orexin receptors |
TW200400035A (en) | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
GB0207449D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
GB0208158D0 (en) * | 2002-03-28 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
GB0207445D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
GB0207443D0 (en) * | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
GB0211759D0 (en) * | 2002-05-22 | 2002-07-03 | Glaxo Group Ltd | Novel compounds |
GB0212355D0 (en) * | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
GB0212357D0 (en) * | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
TW200619212A (en) * | 2004-09-08 | 2006-06-16 | Mitsubishi Pharma Corp | Morpholine derivatives |
ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
TW200724142A (en) | 2005-03-25 | 2007-07-01 | Glaxo Group Ltd | Novel compounds |
TWI389690B (zh) | 2005-03-25 | 2013-03-21 | Glaxo Group Ltd | 新穎化合物(一) |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
JP2009501792A (ja) * | 2005-07-21 | 2009-01-22 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体のモジュレーターとしてのn−ベンジル−モルホリン誘導体 |
AR060536A1 (es) | 2006-04-20 | 2008-06-25 | Glaxo Group Ltd | Agonista del receptor de glucocorticoides y composiciones farmaceuticas |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
CN101506203B (zh) | 2006-08-24 | 2013-10-16 | 诺瓦提斯公司 | 治疗代谢病、心血管病和其他病症的作为硬脂酰辅酶a脱饱和酶(scd)抑制剂的2-(吡嗪-2-基)-噻唑和2-(1h-吡唑-3-基)-噻唑衍生物及相关化合物 |
BRPI0718509A2 (pt) | 2006-09-22 | 2015-09-29 | Novartis Ag | compostos orgânicos heterocíclicos |
CN101595105B (zh) | 2006-12-20 | 2013-01-23 | 诺瓦提斯公司 | 作为scd抑制剂的2-取代的5元杂环化合物 |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
KR20160129109A (ko) | 2008-05-23 | 2016-11-08 | 아미라 파마슈티칼스 인코포레이티드 | 5-리폭시게나아제 활성화 단백질 억제제 |
EP2280946B1 (en) | 2008-06-05 | 2016-02-10 | Glaxo Group Limited | 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases |
EP2280959B1 (en) | 2008-06-05 | 2012-04-04 | Glaxo Group Limited | 4-amino-indazoles |
KR101036913B1 (ko) * | 2008-12-26 | 2011-05-25 | 주식회사 포스코 | 고로의 머드건과 노즐팁 사이의 틈새 메움용 장치 및 방법 |
EP2406255B1 (en) | 2009-03-09 | 2015-04-29 | Glaxo Group Limited | 4-oxadiazol-2-yl-indazoles as inhibitors of pi3 kinases |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
JP2012520845A (ja) | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Itk阻害剤として使用されるピリミジン誘導体 |
WO2010107958A1 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107952A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010107955A2 (en) | 2009-03-19 | 2010-09-23 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING |
JP2012520685A (ja) | 2009-03-19 | 2012-09-10 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害 |
US20120022143A1 (en) | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA) |
JP2012521760A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いたアポトーシスシグナル調節キナーゼ1(ASK1)遺伝子発現のRNA干渉媒介性阻害 |
EP2411018A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) |
JP2012521765A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた細胞内接着分子1(ICAM−1)遺伝子発現のRNA干渉媒介性阻害 |
EP2411019A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120035237A1 (en) | 2009-04-24 | 2012-02-09 | Diane Mary Coe | Pyrazole and triazole carboxamides as crac chann el inhibitors |
WO2010122089A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | N-pyrazolyl carboxamides as crac channel inhibitors |
EA021056B1 (ru) | 2009-04-30 | 2015-03-31 | Глаксо Груп Лимитед | Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ, содержащая их фармацевтическая композиция и их применение в лечении расстройств, опосредованных ненадлежащей активностью pi3-киназ |
JP2013512878A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | 新規化合物 |
WO2011067365A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Benzpyrazole derivatives as inhibitors of p13 kinases |
WO2011067366A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
EP3020393B1 (en) | 2009-12-16 | 2020-10-07 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
EP2613781B1 (en) | 2010-09-08 | 2016-08-24 | GlaxoSmithKline Intellectual Property Development Limited | Indazole derivatives for use in the treatment of influenza virus infection |
PL2614058T3 (pl) | 2010-09-08 | 2015-12-31 | Glaxosmithkline Ip Dev Ltd | Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
WO2012052458A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
US20140005188A1 (en) | 2011-03-11 | 2014-01-02 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
CN104203231A (zh) | 2011-12-01 | 2014-12-10 | 葛兰素集团有限公司 | 治疗和预防眼疾病的方法 |
CA2918938C (en) | 2013-09-22 | 2021-05-18 | Calitor Sciences, Llc | Substituted aminopyrimidine compounds and methods of use |
WO2015148868A1 (en) | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
KR20170003673A (ko) | 2014-05-12 | 2017-01-09 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 감염성 질환을 치료하기 위한 다니릭신을 포함하는 약제 조성물 |
FR3022142B1 (fr) | 2014-06-16 | 2019-07-12 | Universite Paul Sabatier - Toulouse Iii | Inhibition de la chimiokine ccl7 ou de son recepteur ccr3 pour le traitement et le diagnostic du cancer de la prostate |
JP2018527362A (ja) | 2015-09-11 | 2018-09-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 置換されたヘテロアリール化合物および使用方法 |
EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE |
CA3083040A1 (en) | 2018-01-20 | 2019-07-25 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
CA3173172A1 (en) | 2020-03-26 | 2021-09-30 | Christopher D. Kane | Cathepsin inhibitors for preventing or treating viral infections |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63264467A (ja) * | 1986-04-30 | 1988-11-01 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体 |
CZ284687B6 (cs) | 1986-04-30 | 1999-02-17 | Dainippon Pharmaceutical Co., Ltd. | Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi |
JPH01117882A (ja) | 1987-10-30 | 1989-05-10 | Dainippon Pharmaceut Co Ltd | 複素環式カルボン酸アミド誘導体 |
JP3087763B2 (ja) | 1990-11-30 | 2000-09-11 | 三井化学株式会社 | 新規な複素環式化合物およびそれを含有する医薬組成物 |
JPH04247074A (ja) * | 1991-02-01 | 1992-09-03 | Yoshitomi Pharmaceut Ind Ltd | 4−モルホリノ安息香酸誘導体の製造法 |
BR9507666A (pt) * | 1994-05-18 | 1997-09-23 | Nisshin Flour Milling Co | Novos derivados de pirimidina |
CA2189964A1 (en) | 1994-05-18 | 1995-11-23 | Haruhiko Kikuchi | Novel diaminomethylidene derivative |
KR100446099B1 (ko) | 1995-05-23 | 2004-11-10 | 얀센 파마슈티카 엔.브이. | (2-모르폴리닐메틸)벤즈아미드유도체 |
DE19624668A1 (de) | 1996-06-20 | 1998-02-19 | Klinge Co Chem Pharm Fab | Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden |
DE19624704A1 (de) | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalkansäureamide |
IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
CA2329777A1 (en) | 1998-04-27 | 1999-11-04 | Dashyant Dhanak | Ccr-3 receptor antagonists |
WO2000004003A1 (en) | 1998-07-14 | 2000-01-27 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO2000027843A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO2000027800A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
WO2000027835A1 (en) | 1998-11-09 | 2000-05-18 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
TR200101155T2 (tr) | 1998-11-17 | 2001-09-21 | F. Hoffmann-La Roche Ag | 4-Aroil Piperidin CCR-3 Reseptör Antagonistleri III |
AU763960B2 (en) | 1998-11-20 | 2003-08-07 | F. Hoffmann-La Roche Ag | Pyrrolidine derivatives-CCR-3 receptor antagonists |
TR200101397T2 (tr) | 1998-11-20 | 2001-11-21 | F.Hoffmann-La Roche Ag | Piperidin CCR-3 reseptörü antagonistleri |
CN1149214C (zh) | 1998-12-04 | 2004-05-12 | 东丽株式会社 | 三唑并衍生物和含有它们作为有效组分的趋化因子抑制剂 |
EP1140086A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
IL142768A0 (en) | 1998-12-18 | 2002-03-10 | Du Pont Pharm Co | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
AU2482100A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
AU2056800A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | Heterocyclic piperidines as modulators of chemokine receptor activity |
AU2056700A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | 2-substituted-4-nitrogen heterocycles as modulators of chemokine receptor activity |
EP1140087A4 (en) | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-UREIDOALKYL-PIPERIDINES FOR USE AS MODULATORS OF THE ACTIVITY OF CHIMIOKIN RECEPTORS |
EP1158980B1 (en) | 1998-12-18 | 2005-08-24 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
WO2000041685A1 (en) | 1999-01-19 | 2000-07-20 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
US6362201B1 (en) | 1999-03-02 | 2002-03-26 | Merck & Co., Inc. | 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity |
AU3386700A (en) | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
WO2000053172A1 (en) | 1999-03-08 | 2000-09-14 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
AU2942000A (en) | 1999-03-11 | 2000-09-28 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
CA2372887A1 (en) * | 1999-05-25 | 2000-11-30 | Sepracor Inc. | Heterocyclic analgesic compounds and their use |
SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
KR20030031198A (ko) * | 2000-09-29 | 2003-04-18 | 글락소 그룹 리미티드 | 염증 질환 치료용 모르폴린-아세트아미드 유도체 |
-
2001
- 2001-09-28 KR KR10-2003-7004594A patent/KR20030031198A/ko not_active Application Discontinuation
- 2001-09-28 AU AU2001290143A patent/AU2001290143A1/en not_active Abandoned
- 2001-09-28 ES ES01970023.6T patent/ES2527688T3/es not_active Expired - Lifetime
- 2001-09-28 MX MXPA03002814A patent/MXPA03002814A/es unknown
- 2001-09-28 CZ CZ20031195A patent/CZ20031195A3/cs unknown
- 2001-09-28 WO PCT/GB2001/004345 patent/WO2002026722A1/en not_active Application Discontinuation
- 2001-09-28 PL PL01362711A patent/PL362711A1/xx not_active Application Discontinuation
- 2001-09-28 US US10/381,767 patent/US7101882B2/en not_active Expired - Lifetime
- 2001-09-28 CN CNA018196365A patent/CN1678594A/zh active Pending
- 2001-09-28 EP EP01970023.6A patent/EP1324990B1/en not_active Expired - Lifetime
- 2001-09-28 JP JP2002531106A patent/JP5089846B2/ja not_active Expired - Lifetime
- 2001-09-28 NZ NZ525056A patent/NZ525056A/en unknown
- 2001-09-28 AR ARP010104602A patent/AR035205A1/es not_active Application Discontinuation
- 2001-09-28 IL IL15509301A patent/IL155093A0/xx unknown
- 2001-09-28 HU HU0302302A patent/HUP0302302A2/hu unknown
- 2001-09-28 CA CA002423251A patent/CA2423251A1/en not_active Abandoned
- 2001-09-28 BR BR0114323-9A patent/BR0114323A/pt not_active IP Right Cessation
-
2003
- 2003-03-27 US US10/509,519 patent/US20050222147A1/en not_active Abandoned
- 2003-03-28 NO NO20031442A patent/NO20031442L/no unknown
-
2005
- 2005-11-22 US US11/284,544 patent/US7560548B2/en not_active Expired - Lifetime
-
2009
- 2009-02-24 US US12/391,855 patent/US20090163495A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA03002814A (es) | 2003-10-14 |
EP1324990A1 (en) | 2003-07-09 |
EP1324990B1 (en) | 2014-10-29 |
JP5089846B2 (ja) | 2012-12-05 |
US7101882B2 (en) | 2006-09-05 |
AU2001290143A1 (en) | 2002-04-08 |
CZ20031195A3 (cs) | 2003-09-17 |
WO2002026722A1 (en) | 2002-04-04 |
PL362711A1 (en) | 2004-11-02 |
IL155093A0 (en) | 2003-10-31 |
US7560548B2 (en) | 2009-07-14 |
US20090163495A1 (en) | 2009-06-25 |
NZ525056A (en) | 2004-11-26 |
US20060079525A1 (en) | 2006-04-13 |
AR035205A1 (es) | 2004-05-05 |
CN1678594A (zh) | 2005-10-05 |
KR20030031198A (ko) | 2003-04-18 |
JP2004509952A (ja) | 2004-04-02 |
CA2423251A1 (en) | 2002-04-04 |
US20040058923A1 (en) | 2004-03-25 |
ES2527688T3 (es) | 2015-01-28 |
US20050222147A1 (en) | 2005-10-06 |
BR0114323A (pt) | 2003-07-01 |
NO20031442D0 (no) | 2003-03-28 |
NO20031442L (no) | 2003-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0302302A2 (hu) | Morfolin-acetamid-származékok gyulladásos betegségek kezelésére, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0303107A2 (hu) | Gyulladásos betegségek kezelésére alkalmazható vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0303756A2 (hu) | 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények | |
HUP0400699A2 (hu) | Fenetanolaminszármazékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyszerkészítmények | |
SE0202133D0 (sv) | Novel compounds | |
NO20051223L (no) | Oksadiazoler som modulatorer av metabotropisk glutamat reseptor-5. | |
HUP0204474A2 (hu) | 1H-imidazopiridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
CY1107422T1 (el) | Φουραζανοβενζιμιδαζoλες | |
HUP0303637A2 (hu) | Nitrogéntartalmú spirotriciklusos-származékok, eljárás előállításukra, valamint ezeket tartalmazó foszfodiészteráz-7-inhibitorként alkalmazható gyógyszerkészítmények | |
HUP0302960A2 (hu) | Kemokinreceptorhoz kötődő heterociklusos vegyületek, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
HUP0401982A2 (hu) | Indolizinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
NO20050741L (no) | Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den | |
DE69501947T2 (de) | SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER | |
ZA200505273B (en) | Novel compound | |
MXPA02012425A (es) | Compuestos nuevos. | |
HUP0401009A2 (hu) | 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0402458A2 (hu) | Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek | |
TW200616636A (en) | Novel compounds | |
HUP0300743A2 (hu) | Heteroarilszármazékok és alkalmazásuk gyógyszerként | |
HUP0302468A2 (hu) | Alfa V integrin receptor antagonisták és ezeket tartalmazó gyógyszerkészítmények | |
NO20062900L (no) | Nye forbindelser | |
MXPA04000494A (es) | Antagonistas del factor liberador de corticotropina hetero-biciclico. | |
HUP0202249A2 (hu) | Neurotrop pirrolidin-és piperidin-származékok, ezeket tartalmazó gyógyszerkészítmények és a vegyületek alkalmazása | |
MXPA02012426A (es) | Compuestos nuevos. | |
MX2010001081A (es) | Derivados de 1-oxo-1,2-dihidroisoquinolina-5-carboxamidas y de 4-oxo-3,4-dihidroquinazolina-8-carboxamidas, su preparacion y su uso terapeutico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |